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Abstract
Background: Reperfusion injury represents a severe ear-
ly complication following lung transplantation. Among
the pathogenetic factors, the high potassium content of
Euro-Collins® solution is discussed. Material and Meth-
ods: In a pig model of orthotopic left-sided lung trans-
plantation we investigated the effect of Euro-Collins so-
lution (EC: n = 6) versus low potassium dextran (LPD:
Perfadex®: n = 6). Sham-operated (n = 6) animals served
as control. Transplant function, cellular energy metabo-
lism and endothelial morphology served as parameters.
In a clinical investigation, 124 patients were evaluated
following single (EC: n = 31; LPD n = 37) or double (EC: n =
17; LPD n = 39) lung transplantation, whose organs
where preserved with EC (n = 48) or LPD (n = 76). Dura-
tion of ischemia, duration of ventilation and stay on ICU
were registered. Primary transplant function was evalu-
ated according to AaDO2 values. Cause of early death (30
days) was declared. Results: Experimental results: After
flush with EC and 18 h ischemia, a reduction of tissue
ATP content (p ! 0.01 vs inital value and LPD) was noted.
Endothelial damage after ischemia was severe (p ! 0.05
vs control), paO2 was significantly decreased. Clinical
results: In the LPD group, duration of ischemia was lon-
ger for the grafts transplanted first (SLTx and DLTx: p =
0.0009) as well as second (2. organ DLTx: p = 0.045). Pri-
mary transplant function was improved (day 0: SLTx: p =
0.0015; DLTx: p = 0.0095, both vs EC). Duration of ventila-
tion and stay on ICU were shorter (n.s.). Reperfusion inju-
ry-associated death was reduced from 8% (EC) to 0
(LPD). Conclusion: In experimental lung preservation,
LPD lead to an improved graft function. These results
were confirmed in clinical lung transplantation. Clinical
lung preservation, therefore, should be carried out by
use of LPD.
Copyright © 2002 S. Karger AG, Basel
Introduction
Since the first successfully performed lung transplanta-
tion in man by Hardy and colleagues [1] in 1963 this ther-
apeutic approach has become a standard procedure for
the therapy of end-stage pulmonary disease. Up to date
ATP, Ìmol/g dw
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Table 1. Metabolic state and endothelial integrity of native lungs (A), after ischemia (B) and reperfusion (C)
A
(n = 12)
B
EC (n = 6) LPD (n = 6)
C
Sham (n = 6) EC (n = 6) LPD (n = 6)
9.4B0.4 6.8B1.6* 8.2B1.1 7.2B0.7 7.6B2.0 6.0B1.0
SAN, Ìmol/g dw 12.9B0.3 11.8B2.2 12.7B1.1 09.6B1 10.8B1.1 9.7B1.4
ECP 0.82B0.02 0.69B0.06 * 0.75B0.03 0.85B0.02 0.72B0.06 0.74B0.02
PCr/tCr 0.34B0.03 0.25B0.06 0.38B0.04 0.23B0.03 0.24B0.03 0.4B0.03
Glucose, Ìmol/g dw 23.9B1.8 133B33** 3.7B0.6 13.3B2.7 33.0B4## 16.2B4
Lactate, Ìmol/g dw 14.4B1.4 48.8B6.1** 23.5B2.2 20.8B3.9 33.6B7.2# 25.6B5.2
Endothelium 1.7B0.2 3B0.3+ 1.8B0.4 3.7B0.3** 4B0.4**, ++ 3.7B0.2**, ***
SAN = Sum of adenine nucleotides; ECP = energy charge potential; + p ! 0.05 vs A; ++ p ! 0.05 vs B; * p ! 0.01 vs
A; ** p ! 0.0001 vs A; *** p ! 0.0001 vs B; # p ! 0.05 vs A und B; ## p ! 0.001 vs B. All values are mean B SD.
more than 12,000 lung transplantations have been per-
formed world-wide [2]. An essential factor determining
the outcome following lung transplantation is organ pres-
ervation. Most lung transplanting centers around the
world use Euro-Collins® (EC) solution for flush perfusion
of donor organs. This method of organ preservation leads
to ischemia-reperfusion injury (IRI) in more than 50% of
all organs with an ensuing mortality rate as high as 5%
[3–5].
As major pathogenetic factor the high potassium con-
tent of the Euro-Collins solution has been discussed,
which induces a strong vasoconstriction of the pulmonary
vessel bed [6] and reduces the vascular relaxation capacity
of pulmonary vessels [7].
Experimental studies have shown that the use of a low-
potassium dextran (LPD: Perfadex®), which is an extra-
cellular preservation solution containing dextran as os-
motic active component results in an improved primary
transplant function [8, 9].
In our clinical experience the use of Euro-Collins pres-
ervation solution causes an ischemia-reperfusion injury in
65% with a mortality rate of 6%. Prior to introduction of
low-potassium dextran solution as an alternate preserva-
tion fluid in the clinical practice we therefore evaluated
the solution in a bovine model of orthotopic left-sided
lung transplantation [10].
Material and Method
Experimental Studies
In a model of orthotopic left-sided single lung transplantation
native pigs of either sex were paired by weight. Twelve pigs served as
donors, 12 pigs served as recipient animals. The donor organs were
preserved by Euro-Collins solution (n = 6) or low-potassium dextran
(n = 6) alternatively. A group of sham-operated animals served as
control (n = 6). The experimental protocol was approved by the gov-
ernment of Oberbayern.
Donor Procedure
Under general anesthesia heparin sodium was administered in-
travenously (500 IE/kg) followed by intravenous application of Epo-
prostenol (200 Ìg). After induction of cardiac arrest both lungs were
perfused with pre-chilled Euro-Collins solution (EC: n = 6; 150 ml/kg
b.w.) or low-potassium dextran (LPD; n = 6, 150 ml/kg b.w.) with a
perfusion pressure of 50 cm water. Ventilation was continued during
the flush procedure, at the end of the perfusion both lungs were
explanted, dissected free from surrounding tissue and preserved in
Ringer solution (4°C) while insufflated with pure oxygen.
Recipient Procedure
Following 18 h of ischemia a left-sided single lung transplantation
was performed in both groups. A group of sham-operated animals
(n = 6) served as control. Serial measurements of the pulmonary and
systemic hemodynamics (MAP) and calculation of the pulmonary
vascular resistance (PVR) were carried out right before the transplan-
tation and every hour during the reperfusion period. Measurements
were performed in the single lung ventilation and perfusion state,
excluding the native lung from perfusion and ventilation by clamping
of the right hilus.
For metabolic analysis biopsies from the apex of the upper lobe
were taken from normal lungs (A: left recipient lung prior to pneu-
monectomy), at the end of preservation (B: right preserved lung) and
at the end of reperfusion (C: transplanted lung). Probes were shock-
frozen and processed for enzymatic tests, determining tissue levels of
adenosine triphosphate (ATP), glucose and lactate. Sum of adenine
nucleotides (SAN = ATP + ADP + AMP) and energy charge potential
(ECP = ATP + 0.5 ADP/SAN) were calculated. Morphological analy-
sis was carried out on biopsies of four lung areas. Endothelial cell
integrity was evaluated and classified as 0 (normal structure) up to 5
(severe endothelial damage with loss of endothelial cells). Biopsies
were taken from non-treated lungs (A: left lung of recipient prior to
pneumonectomy), at the end of ischemia (B: donor right lung) and at
the end of reperfusion (C: lung graft).
MAP, mmHg
Age, years 
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Table 2. Pulmonary hemodynamic and gas exchange
pre Tx
(n = 24)
1 h post reperfusion
Sham (n = 6) EC (n = 4) LPD (n = 6)
6 h post reperfusion
Sham (n = 6) EC (n = 6) LPD (n = 6)
84B5 98B10 77B10 89B6 87B6 68B12 78B10
PVR, dyn Ws Wcm–5 387B30 445B28 2,056B1,092*, ** 830B118 748B63 1,787B380# 1,670B177
PaO2, mm Hg 458B15 478B38 374B99 325B75 492B43 276B81#, ## 436B47
PVR = Pulmonary vascular resistance; * p ! 0.05 vs LPD; ** p ! 0.01 vs sham; # p ! 0.05 vs sham;
## p ! 0.01 vs LPD; all values as mean B SD.
Table 3. Donor data
EC (n = 48) LPD (n = 76) p
31B11 35 B 12
Gender
Male 27 40
Female 21 36
Cause of death
Brain injury 26 34
SAB 15 28
Others 7 14
Duration of ischemia, h
1. lung 4.2B1.0 4.9B1.0 0.0009
2. lung 6.0B1.6 6.9B1.4 0.045
Mean B SD.
Statistics
Data are group mean B SEM. Results obtained from functional,
morphological and metabolic parameters were statistically analyzed
using ANOVA and Fisher's exact test. Dependent variables were
tested by Student’s t test. Differences between groups were consid-
ered significant at p ! 0.05.
Results
A significant decrease of ATP and ECP vs. non-treated
lungs of group A was observed in the EC-preserved ani-
mals at the end of ischemia. The tissue content of glucose
and lactate was significantly increased. All other groups
showed a clear decrease of the glucose content and an
increase of tissue lactate concentration (NS). At the end of
reperfusion parameters of the energy metabolism did not
show significant differences when compared with the ini-
tial values. Endothelial cells from lungs of group A were
unaltered and showed a discrete swelling in some cases
(table 1).
After 18 h of ischemia lungs perfused with Euro-Col-
lins solution showed a significant increase in endothelial
cell swelling with a vacuolisation of the cells. Lungs of the
LPD group were not significantly altered as compared to
group A. At the end of reperfusion (C) all lungs of the
study groups showed medium to severe endothelial alter-
ations.
After 1 h of reperfusion 4 of 6 animals of the EC-group
and all animals of the LPD group (n = 6) tolerated the
clamping of the right native lung. Oxygenation capacity
and MAP did not show significant differences, the PVR
was highest in the EC group. After 6 h of reperfusion func-
tional measurements were carried out in all animals of
both groups. In the EC group paO2 was lowest and PVR
highest, the LPD group showed PVR values significantly
increased compared to the initial values (table 2).
Patients and Methods
Since the first lung transplantation in our institution in
August 1991, 141 lung transplantations were performed
in 138 patients until September 2001. Since not all donor
organs were explanted by our own team, 12% (n = 17) of
the donor organs were preserved by means of other than
Euro-Collins or low-potassium dextran solution. This
analysis focuses on the 124 patients where donor organs
were preserved using Euro-Collins (n = 48) or low-potas-
sium dextran (n = 76).
The analysis of donor data showed a similar distribu-
tion of age, gender and causes of death. In the LPD-group
duration of ischemia was significantly longer when com-
pared with the Euro-Collins-preserved organs (table 3).
Transplantations were performed in 70 female and 54
male patients, with a significantly lower mean recipient
age in the EC group.
The leading indications for lung transplantation were
pulmonary fibrosis, emphysema and cystic fibrosis (CF).
Age, years
AaDO2 (day 0)
Duration of operation, min
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Table 4. Parameters of organ recipients
EC (n = 48) LPD (n = 76)
41B13 46B12*
Gender
Male 23 31
Female 25 45
Disease
Fibrosis 20 24
Emphysema 13 28
CF 11 10
Others 4 14
Tx-Type
SLTx 31 37
DLTx 17 39
SLTx = Single lung transplantation; DLTx = double lung trans-
plantation; CF = cystic fibrosis; * p ! 0.0001; all values are mean B
SD.
Table 5. Postoperative course of all patients
EC (n = 48) LPD (n = 76) p
276B170 173B136 0.0004
AaDO2 (day 1) 143B135 118B116 ns
AaDO2 (day 3) 100B117 73B54 ns
Ventilation (days) 21B45 11B15 ns
Stay on ICU (days) 33B48 21B22 ns
Mean B SD.
Table 6. Intra- und postoperative course
following single- (SLTx) and double lung
transplantation (DLTx)
SLTx
EC (n = 31) LPD (n = 32)
DLTx
EC (n = 17) LPD (n = 38)
223B157 191B121 367B104 347B156
Blood units 2.2B5.0 1.5B3.1 6.8B5.0 6.4B6.8
HLM (%) 16 31 47 50
AaDO2 (day 0) 232B142 140B88 * 336B191 201B163**
AaDO2 (day 1) 140B129 110B85 141B150 126B138
AaDO2 (day 3) 101B113 71B53 98B126 74B56
Ventilation (days) 18B41 7B10 25B54 14B17
Mean B SD; * p = 0.0015; ** p = 0.0095.
Rare indications were lymphangioleiomyomatosis (n = 5),
pulmonary hypertension (n = 5), exogeneous allergic
alveolitis (n = 2), cystic lung disease (n = 2), bronchiectasis
(n = 1) and obliterative bronchiolitis (n = 2). One trans-
plantation was carried out as re-transplantation due to
primary graft failure.
Single-lung transplantation was carried out in 68 cases,
while double-lung transplantation was necessary in 56
patients (table 4).
The postoperative graft function was evaluated accord-
ing to the calculated alveolar arterial oxygen pressure dif-
ference (AaDO2).
In the LPD group a significantly lower AaDO2 was
observed during the first 24 h following transplantation.
The subsequently better gas exchange function allowed
for a shorter duration of ventilator therapy and a shorter
intensive care unit stay in patients receiving LPD-pre-
served organs (table 5).
Comparison of the LPD and Euro-Collins group indi-
cates comparable length of surgery, blood transfusion
requirements and a significantly improved gas exchange
despite significantly more patients requiring extracorpor-
eal circulation in the LPD-group during surgery. This
observation was independent of single-lung or double-
lung transplantation (table 6).
30-day mortality in the LPD group was lower than in
the EC group. The development of severe ischemia reper-
fusion injury led to the death of 3 patients in the EC
group, while after introduction of low-potassium dextran
as preservation medium severe reperfusion injuries were
no more seen (table 7).
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Discussion
The development of ischemia-reperfusion injury fol-
lowing lung transplantation leads to increased morbidity
and mortality rates. Clinical standard in most transplant-
ing centers for the prevention of this severe condition is
the administration of heparin and vasodilatory agents,
followed by pulmonary flush perfusion with pre-chilled
Euro-Collins solution. Use of this method leads to the
development of an ischemia-reperfusion injury in more
than 50% of all patients, which may cause a mortality rate
as high as 5% [5]. In our institution the use of Euro-Col-
lins solution was responsible for reperfusion injury in
60% of our patients with a subsequent mortality rate of
8%.
Reports in the literature have indicated that the use of
low-potassium dextran (Perfadex) as preservation me-
dium might be beneficial when compared to Euro-Collins
solution. As pathophysiological rationale for the develop-
ment of an ischemia-reperfusion injury by use of Euro-
Collins solution, a direct effect of the high-potassium con-
tent of Euro-Collins on endothelial cells of the pulmonary
vasculature has been discussed [6]. An observed increase
of the pulmonary vascular resistance during reperfusion
seemed to be caused by a reduction of endothelial NO
synthesis, which by means of reduction of the vascular
relaxation capacity may lead to an increase of their resis-
tance [7, 14]. Experimental studies on isolated pulmonary
artery segments by Kimblad and co-workers [15] showed
a significantly improved relaxation capacity of these ves-
sels after preservation with low-potassium dextran. Anal-
ysis of isolated type-II pneumocytes showed a decreased
cytotoxicity after use of LPD [16]. In our own experimen-
tal studies using a model of orthotopic left-sided single-
lung transplantation in pigs a significantly improved graft
function was observed following lung preservation with
low-potassium dextran [10].
Table 7. Cause of 30-day mortality
EC (n = 48) LPD (n = 76)
30-day mortality, % 12.5 7.9
IRI 3 0
Sepsis 1 2
Others 2 4
IRI = Ischemia reperfusion injury.
In more sophisticated studies dealing with the mecha-
nisms of an improved graft function our group was able to
show that low-potassium dextran as compared to Euro-
Collins leads to a significantly decreased lipid peroxida-
tion of lung tissue, associated with a significant reduction
of reperfusion injury [17].
These results are the basis of our decision to introduce
low-potassium dextran (Perfadex) into clinical lung pres-
ervation. Our clinical results were able to demonstrate
that the use of low-potassium dextran resulted in an
improved primary graft function. The mortality rate of
8%, caused by severe ischemia-reperfusion injuries,
which was observed after the use of Euro-Collins solution
was abolished [18]. This observation was confirmed by
Keshavjee [19] and Haverich [20] and lead to a substitu-
tion of Euro Collins by LPD.
The follow-up of the transplant patients must show,
whether a reduced ischemia-reperfusion injury and there-
fore improved immediate graft function may have its
effect on long-term graft function. This paper gives an
example, how experimental work on a clinically relevant
problem can result in a successful transfer into clinical
practice.
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